

# Eric Pasmant

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3296667/publications.pdf>

Version: 2024-02-01

96  
papers

4,871  
citations

145106

33  
h-index

111975

67  
g-index

101  
all docs

101  
docs citations

101  
times ranked

8938  
citing authors

#	ARTICLE	IF	CITATIONS
1	KDM1A inactivation causes hereditary food-dependent Cushing syndrome. <i>Genetics in Medicine</i> , 2022, 24, 374-383.	1.1	27
2	Identification of three clinical neurofibromatosis 1 subtypes: Latent class analysis of a series of 1351 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 739-743.	1.3	0
3	RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 1237-1252.	3.3	12
4	Redifferentiating Effect of Larotrectinib in <i>NTRK</i> -Rearranged Advanced Radioactive-Iodine Refractory Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 594-598.	2.4	19
5	Transcriptome in paraffin samples for the diagnosis and prognosis of adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2022, 186, 607-617.	1.9	2
6	Noninvasive Prenatal Diagnosis of a Paternally Inherited <i>MEN1</i> Pathogenic Splicing Variant. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1367-e1373.	1.8	1
7	Natural history of NF1 c.2970_2972del p.(Met992del): confirmation of a low risk of complications in a longitudinal study. <i>European Journal of Human Genetics</i> , 2022, 30, 291-297.	1.4	5
8	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. <i>Cancer Discovery</i> , 2022, 12, 1435-1448.	7.7	28
9	VEGF and VEGFR family members are expressed by neoplastic cells of NF1-associated tumors and may play an oncogenic role in malignant peripheral nerve sheath tumor growth through an autocrine loop. <i>Annals of Diagnostic Pathology</i> , 2022, 60, 151997.	0.6	2
10	COVID-19: Discovery, diagnostics and drug development. <i>Journal of Hepatology</i> , 2021, 74, 168-184.	1.8	302
11	Severe Phenotype in Patients with Large Deletions of NF1. <i>Cancers</i> , 2021, 13, 2963.	1.7	15
12	Prenatal features and neonatal management of severe hyperparathyroidism caused by the heterozygous inactivating calcium-sensing receptor variant, Arg185Gln: A case report and review of the literature. <i>Bone Reports</i> , 2021, 15, 101097.	0.2	3
13	Malignant histiocytosis with a Langerhans cell subtype: A report on the diagnostic and therapeutic challenge. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 92, 102623.	0.6	0
14	Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic options. <i>Journal of Medical Genetics</i> , 2020, 57, 104-108.	1.5	16
15	Proteome analysis of formalin-fixed paraffin-embedded colorectal adenomas reveals the heterogeneous nature of traditional serrated adenomas compared to other colorectal adenomas. <i>Journal of Pathology</i> , 2020, 250, 251-261.	2.1	6
16	NF1-like optic pathway gliomas in children: clinical and molecular characterization of this specific presentation. <i>Neuro-Oncology Advances</i> , 2020, 2, i98-i106.	0.4	4
17	BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis. <i>Journal of Immunotherapy</i> , 2020, 8, e000275.		11
18	Identification of <i>TP53</i> mutated group using a molecular and immunohistochemical classification of endometrial carcinoma to improve prognostic evaluation for adjuvant treatments. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 640-647.	1.2	13

#	ARTICLE	IF	CITATIONS
19	Should we genotype the sperm of fathers from patients with "de novo" mutations?. European Journal of Endocrinology, 2020, 182, C1-C3.	1.9	13
20	Phosphorylation of Merlin by Aurora A kinase appears necessary for mitotic progression. Journal of Biological Chemistry, 2019, 294, 12992-13005.	1.6	7
21	One NF1 Mutation may Conceal Another. Genes, 2019, 10, 633.	1.0	5
22	High Positive Correlations between ANRIL and p16-CDKN2A/p15-CDKN2B/p14-ARF Gene Cluster Overexpression in Multi-Tumor Types Suggest Deregulated Activation of an ANRIL-ARF Bidirectional Promoter. Non-coding RNA, 2019, 5, 44.	1.3	21
23	BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation. Nature Communications, 2019, 10, 348.	5.8	105
24	UMD-MEN1 Database: An Overview of the 370 MEN1 Variants Present in 1676 Patients From the French Population. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 753-764.	1.8	39
25	NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas. Cancer Medicine, 2019, 8, 4330-4337.	1.3	14
26	The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas. PLoS ONE, 2019, 14, e0214416.	1.1	10
27	EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6075-6080.	3.3	42
28	Proposition of adjustments to the ACMG-CAMP framework for the interpretation of MEN1 missense variants. Human Mutation, 2019, 40, 661-674.	1.1	21
29	McCune Albright syndrome is a genetic predisposition to intraductal papillary and mucinous neoplasms of the pancreas associated pancreatic cancer in relation with GNAS somatic mutation: a case report. Medicine (United States), 2019, 98, e18102.	0.4	7
30	"MPNST Epigenetics" Letter. Molecular Cancer Research, 2019, 17, 2139-2139.	1.5	1
31	Combination of the MEK Inhibitor Trametinib and Pyvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models. Blood, 2019, 134, 2671-2671.	0.6	0
32	Abstract 4955: Impact of PD-1, PD-L1 and EB13 on prognosis in a cohort of localized high grade undifferentiated pleomorphic sarcoma patients. , 2019, , .		0
33	Neurofibromatosis type 2 French cohort analysis using a comprehensive NF2 molecular diagnostic strategy. Neurochirurgie, 2018, 64, 335-341.	0.6	6
34	Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis. Neuro-Oncology, 2018, 20, 917-929.	0.6	48
35	Involvement of Aryl hydrocarbon receptor in myelination and in human nerve sheath tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1319-E1328.	3.3	27
36	Detection and monitoring of circulating tumor DNA in adrenocortical carcinoma. Endocrine-Related Cancer, 2018, 25, L13-L17.	1.6	22

#	ARTICLE	IF	CITATIONS
37	Humanized Mouse Model to Study Type 1 Diabetes. <i>Diabetes</i> , 2018, 67, 1816-1829.	0.3	20
38	BRCA2 Loss-of-Function and High Sensitivity to Cisplatin-Based Chemotherapy in a Patient With a Pleomorphic Soft Tissue Sarcoma: Effect of Genomic Medicine. <i>American Journal of the Medical Sciences</i> , 2018, 356, 404-407.	0.4	5
39	Abstract 5511: Characterization of molecular and functional consequences of somatic NF1 mutations in non-small cell lung cancers. , 2018, , .		0
40	Abstract 4609: High-grade TP53-mutated endometrial carcinomas have decreased NRF2 antioxidant activity. , 2018, , .		0
41	Primary giant cell tumor of the common bile duct: No mutation <i>H3F3A</i> found. <i>Pathology International</i> , 2017, 67, 225-227.	0.6	0
42	Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 421-426.	1.5	54
43	Familial small-intestine carcinoids: Chromosomal alterations and germline inositol polyphosphate multikinase sequencing. <i>Digestive and Liver Disease</i> , 2017, 49, 98-102.	0.4	9
44	Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on <i>BRAF</i> <sup>V600E</sup> Melanoma Lines with Vemurafenib. <i>Cancer Immunology Research</i> , 2017, 5, 582-593.	1.6	17
45	Calling Chromosome Alterations, DNA Methylation Statuses, and Mutations in Tumors by Simple Targeted Next-Generation Sequencing. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 776-787.	1.2	7
46	Synovial Sarcomas Do Not Show H3K27 Trimethylation Loss Using Immunohistochemistry. <i>American Journal of Surgical Pathology</i> , 2017, 41, 283-285.	2.1	5
47	Identification by FFPE RNA-Seq of a new recurrent inversion leading to <i>RBM10</i> - <i>TFE3</i> fusion in renal cell carcinoma with subtle <i>TFE3</i> break-apart FISH pattern. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 541-548.	1.5	32
48	<i>SETD2</i> and <i>DNMT3A</i> screen in the Sotos-like syndrome French cohort. <i>Journal of Medical Genetics</i> , 2016, 53, 743-751.	1.5	54
49	Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 1395-1404.	2.9	75
50	Expression of <i>ANRIL</i> "Polycomb Complexes" <i>CDKN2A/B/ARF</i> Genes in Breast Tumors: Identification of a Two-Gene ( <i>EZH2/CBX7</i> ) Signature with Independent Prognostic Value. <i>Molecular Cancer Research</i> , 2016, 14, 623-633.	1.5	84
51	Neurofibromatosis Type 1 Molecular Diagnosis: The RNA Point of View. <i>EBioMedicine</i> , 2016, 7, 21-22.	2.7	3
52	Copy number variants and rasopathies: germline KRAS duplication in a patient with syndrome including pigmentation abnormalities. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 101.	1.2	7
53	High specificity and sensitivity of NRAS Q61R immunohistochemistry (IHC) in melanomas. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 572-573.	0.6	6
54	RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action. <i>Oncotarget</i> , 2016, 7, 38892-38907.	0.8	116

#	ARTICLE	IF	CITATIONS
55	Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells. <i>Oncotarget</i> , 2016, 7, 35753-35767.	0.8	46
56	Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis. <i>Genes and Development</i> , 2015, 29, 2547-2562.	2.7	77
57	NF1 single and multi-exons copy number variations in neurofibromatosis type 1. <i>Journal of Human Genetics</i> , 2015, 60, 221-224.	1.1	15
58	Chaperoning 5S RNA assembly. <i>Genes and Development</i> , 2015, 29, 1432-1446.	2.7	54
59	Unraveling the intrafamilial correlations and heritability of tumor types in MEN1: a Groupe d'Étude des Tumeurs Endocrines study. <i>European Journal of Endocrinology</i> , 2015, 173, 819-826.	1.9	29
60	SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia. <i>Oncogene</i> , 2015, 34, 631-638.	2.6	47
61	Neurofibromatosis type 1 molecular diagnosis: what can NGS do for you when you have a large gene with loss of function mutations?. <i>European Journal of Human Genetics</i> , 2015, 23, 596-601.	1.4	97
62	Uveal melanoma hepatic metastases mutation spectrum analysis using targeted next-generation sequencing of 400 cancer genes. <i>British Journal of Ophthalmology</i> , 2015, 99, 437-439.	2.1	31
63	RAS MAPK inhibitors deregulation in leukemia. <i>Oncoscience</i> , 2015, 2, 930-931.	0.9	4
64	The Activation of the WNT Signaling Pathway Is a Hallmark in Neurofibromatosis Type 1 Tumorigenesis. <i>Clinical Cancer Research</i> , 2014, 20, 358-371.	3.2	44
65	Mutations in <i>SETD2</i> cause a novel overgrowth condition. <i>Journal of Medical Genetics</i> , 2014, 51, 512-517.	1.5	96
66	Immunohistochemistry versus next-generation sequencing for the routine detection of BRAF V600E mutation in melanomas. <i>Human Pathology</i> , 2014, 45, 1983-1984.	1.1	8
67	PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. <i>Nature</i> , 2014, 514, 247-251.	13.7	386
68	Abstract LB-79: PRC2 loss amplifies Ras-driven transcription and sensitizes cancers to bromodomain inhibitor-based combination therapies. , 2014, , .		0
69	MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis. <i>BMC Genomics</i> , 2013, 14, 473.	1.2	46
70	Relevance of MPNST cell lines as models for NF1 associated-tumors. <i>Journal of Neuro-Oncology</i> , 2013, 114, 353-355.	1.4	5
71	<i>NF1</i> Molecular Characterization and Neurofibromatosis Type I Genotype-Phenotype Correlation: The French Experience. <i>Human Mutation</i> , 2013, 34, 1510-1518.	1.1	140
72	Abstract PR15: SUZ12: A novel tumor suppressor and potential biomarker for efficacy of BRD4 inhibition. <i>Cancer Research</i> , 2013, 73, PR15-PR15.	0.4	2

#	ARTICLE	IF	CITATIONS
73	Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. <i>Human Molecular Genetics</i> , 2012, 21, 5397-5405.	1.4	126
74	First description of ABCB4 gene deletions in familial low phospholipid-associated cholelithiasis and oral contraceptives-induced cholestasis. <i>European Journal of Human Genetics</i> , 2012, 20, 277-282.	1.4	42
75	Neurofibromatosis type 1: from genotype to phenotype. <i>Journal of Medical Genetics</i> , 2012, 49, 483-489.	1.5	133
76	Two independent de novo mutations as a cause for neurofibromatosis type 1 and Noonan syndrome in a single family. <i>American Journal of Medical Genetics, Part A</i> , 2012, 158A, 2290-2291.	0.7	4
77	Review and update of <i>SPRED1</i> mutations causing legius syndrome. <i>Human Mutation</i> , 2012, 33, 1538-1546.	1.1	81
78	Characterization of the nonallelic homologous recombination hotspot PRS3 associated with type-3 <i>NF1</i> deletions. <i>Human Mutation</i> , 2012, 33, 372-383.	1.1	28
79	Modifier Genes in NF1. , 2012, , 269-285.		1
80	<i>ANRIL</i> , a long, noncoding RNA, is an unexpected major hotspot in GWAS. <i>FASEB Journal</i> , 2011, 25, 444-448.	0.2	413
81	Identification of Genes Potentially Involved in the Increased Risk of Malignancy in NF1-Microdeleted Patients. <i>Molecular Medicine</i> , 2011, 17, 79-87.	1.9	46
82	A severe neonatal presentation of factor II deficiency. <i>European Journal of Haematology</i> , 2011, 87, 464-466.	1.1	6
83	Different sized somatic NF1 locus rearrangements in neurofibromatosis-1-associated malignant peripheral nerve sheath tumors. <i>Journal of Neuro-Oncology</i> , 2011, 102, 341-346.	1.4	9
84	Role of Noncoding RNA ANRIL in Genesis of Plexiform Neurofibromas in Neurofibromatosis Type 1. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1713-1722.	3.0	106
85	NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. <i>Human Mutation</i> , 2010, 31, E1506-E1518.	1.1	208
86	Differential Expression of <i>CCN1</i> , <i>CYR61</i> , <i>CCN3/NOV</i> , <i>CCN4/WISP1</i> , and <i>CCN5/WISP2</i> in Neurofibromatosis Type 1 Tumorigenesis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 60-69.	0.9	16
87	Unraveling the genetic predisposition of ribavirin-induced anaemia. <i>Journal of Hepatology</i> , 2010, 53, 971-973.	1.8	4
88	VKORC1 and CYP2C9 genetic polymorphisms in hepatic or portal vein thrombosis. <i>Thrombosis Research</i> , 2010, 126, e134-e136.	0.8	8
89	Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. <i>Human Molecular Genetics</i> , 2009, 18, 2768-2778.	1.4	129
90	SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. <i>Journal of Medical Genetics</i> , 2009, 46, 425-430.	1.5	103

#	ARTICLE	IF	CITATIONS
91	Detection and Characterization of NF1 Microdeletions by Custom High Resolution Array CGH. Journal of Molecular Diagnostics, 2009, 11, 524-529.	1.2	31
92	SPRED1 disorder and predisposition to leukemia in children. Blood, 2009, 114, 1131-1131.	0.6	40
93	Characterization of a 7.6-Mb germline deletion encompassing the NF1 locus and about a hundred genes in an NF1 contiguous gene syndrome patient. European Journal of Human Genetics, 2008, 16, 1459-1466.	1.4	30
94	A natural variant with a point mutation resulting in a homozygous Arg to His substitution at position 388 in prothrombin. Haematologica, 2008, 93, 799-800.	1.7	3
95	Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype phenotype relationships and overlap with Costello syndrome. Journal of Medical Genetics, 2007, 44, 763-771.	1.5	221
96	Characterization of a Germ-Line Deletion, Including the Entire INK4/ARF Locus, in a Melanoma-Neural System Tumor Family: Identification of ANRIL, an Antisense Noncoding RNA Whose Expression Coclusters with ARF. Cancer Research, 2007, 67, 3963-3969.	0.4	582